DK0697889T3 - Kombineret behandling af jerndepletering og IgG antistof - Google Patents

Kombineret behandling af jerndepletering og IgG antistof

Info

Publication number
DK0697889T3
DK0697889T3 DK94913873T DK94913873T DK0697889T3 DK 0697889 T3 DK0697889 T3 DK 0697889T3 DK 94913873 T DK94913873 T DK 94913873T DK 94913873 T DK94913873 T DK 94913873T DK 0697889 T3 DK0697889 T3 DK 0697889T3
Authority
DK
Denmark
Prior art keywords
igg antibody
combined treatment
tumor cells
iron depletion
depletion
Prior art date
Application number
DK94913873T
Other languages
Danish (da)
English (en)
Inventor
John D Kemp
Original Assignee
Univ Iowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa filed Critical Univ Iowa
Application granted granted Critical
Publication of DK0697889T3 publication Critical patent/DK0697889T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94913873T 1993-04-29 1994-01-25 Kombineret behandling af jerndepletering og IgG antistof DK0697889T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5467993A 1993-04-29 1993-04-29
PCT/US1994/000911 WO1994025066A1 (fr) 1993-04-29 1994-01-25 TRAITEMENT COMBINANT UNE DEPLETION FERRIQUE ET UN ANTICORPS IgG

Publications (1)

Publication Number Publication Date
DK0697889T3 true DK0697889T3 (da) 2003-03-17

Family

ID=21992780

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94913873T DK0697889T3 (da) 1993-04-29 1994-01-25 Kombineret behandling af jerndepletering og IgG antistof

Country Status (10)

Country Link
EP (1) EP0697889B1 (fr)
JP (1) JPH09500868A (fr)
AT (1) ATE227585T1 (fr)
AU (1) AU699915B2 (fr)
CA (1) CA2161656A1 (fr)
DE (1) DE69431717T2 (fr)
DK (1) DK0697889T3 (fr)
ES (1) ES2187521T3 (fr)
PT (1) PT697889E (fr)
WO (1) WO1994025066A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426098T3 (es) * 2009-07-16 2013-10-21 Institut National de la Santé et de la Recherche Médicale Composiciones farmacéuticas y su uso en el tratamiento del cáncer
WO2020127885A1 (fr) * 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions pour le traitement de cancers et de cancers résistants
CN114217071B (zh) * 2021-12-01 2023-11-14 柏荣诊断产品(上海)有限公司 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒

Also Published As

Publication number Publication date
ES2187521T3 (es) 2003-06-16
EP0697889B1 (fr) 2002-11-13
DE69431717T2 (de) 2003-09-18
DE69431717D1 (de) 2002-12-19
EP0697889A1 (fr) 1996-02-28
CA2161656A1 (fr) 1994-11-10
JPH09500868A (ja) 1997-01-28
EP0697889A4 (fr) 1997-01-02
WO1994025066A1 (fr) 1994-11-10
ATE227585T1 (de) 2002-11-15
AU6586094A (en) 1994-11-21
AU699915B2 (en) 1998-12-17
PT697889E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
HK1054949A1 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations t
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
HUT72835A (en) Monoclonal antibodies to rapamicin (derivatives), immunoassay kits for using them, hybridoma cell lines and conjugates containing rapamicin- and protein-part
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP0182467A3 (en) Human hybridoma fusion partner for production of human monoclonal antibodies
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DK0743856T3 (da) Antigenbaserede heteropolymerer til behandling af autoimmune sygdomme
MY106561A (en) Method of making factor-dependent human b cell lines
NZ509536A (en) Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
EP0145333A3 (en) Monoclonal antibody candida albicans cytoplasmic antigens and methods of preparing same
GR3031518T3 (en) Selective system scan for multizone radiotelephone subscriber units.
YU46386B (sh) Monoklonska antitela i antigeni za ljudske karcinome pluća koji ne pripadaju tipu "malih ćelija"
DK0697889T3 (da) Kombineret behandling af jerndepletering og IgG antistof
DK0387873T3 (da) Anti-humant spermaantistof, fremstilling og anvendelse deraf
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
EP0722489A4 (fr) Anticorps monoclonaux reconnaissant les recepteurs flk-2 et isolement de populations de cellules souches primitives hematopoietiques
WO1987007302A3 (fr) ANTICORPS MONOCLONAUX DES RECEPTEURS IgE DES LYMPHOCYTES HUMAINS, HYBRIDOMES PRODUISANT DE TELS ANTICORPS, ET KITS POUR UTILISER CES ANTICORPS
FR2621127B1 (fr) Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
EP0089771A3 (fr) ATCC HB 8116 et son anticorps monoclonal anti-h-y, hyclonalan
UA39209C2 (uk) Моноклональне антитіло, що інгібує хомінг кровотворних стовбурових клітин і розпізнає поверхневий антіген стромальної клітини селезінки, гібридома, яка його продукує
DK557187A (da) Murin hybridoma lym-1, dermed fremstillet monoklonalt antistof og fremgangsmaade til fremstilling af antistoffet